Biotech company buys hearing loss drug
Hough Ear Institute's pharmaceutical partner, Auditus LLC, has an agreement for Oblato Inc. to assume exclusive rights to a drug known as NHPN-1010 to advance clinical research in…
Hough Ear Institute's pharmaceutical partner, Auditus LLC, has an agreement for Oblato Inc. to assume exclusive rights to a drug known as NHPN-1010 to advance clinical research in…